UNSPSC 51332828: Thioproperazine

This classification denotes an antipsychotic agent with the molecular formula C22H30N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJ050AQ56X, chemically known as 10h-phenothiazine-2-sulfonamide, n,n-dimethyl-10-(3-(4-methyl-1-piperazinyl)propyl)- but generally known as thioproperazine, which bears US NIH Compound Identifier 9429. European Medicines Agency schedules Thioproperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10983MIG.

UNSPSC 51332828 Thioproperazine is a Commodity code that in practice captures state and local procurement of pharmaceutical products, naloxone, drug deactivation systems, and related medical supplies distributed through government health and human services channels. The code shows a mix of direct-purchase and cooperative purchasing activity, with issuing bodies including county health departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating on behalf of multiple member jurisdictions. Procurement under this code centers on bulk acquisition of medications and medical countermeasures for community health initiatives, emergency response programs, and pharmacy benefit programs serving government employees and populations.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, including shipping at vendor cost, on a two-year term with one-year renewal option. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and wholesaler channels, targeting vendors experienced with self-insured health plans and negotiated net pricing models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (response deadline March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co.—with pricing evaluation weighted 75 percent on price competitiveness and 25 percent on administrative, compliance, and EDI factors.